Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Toxicological Sciences

• Publication date

  2006-12-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1093/TOXSCI/KFL096PMID 16945988
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Monoclonal Antibodies and Multifunctional Cytochrome P450: Drug Metabolism as Paradigm

  2006influential reference
• Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

  2006cited by this paper
• Depletion of Latent HIV-1 Infection In Vivo: A Proof-of-Concept Study

  2006cited by this paper
• Depletion of latent HIV-1 infection in vivo: a proof-of-concept study.

  2005cited by this paper
• Substrate selectivity of human cytochrome P450 2C9: importance of residues 476, 365, and 114 in recognition of diclofenac and sulfaphenazole and in mechanism-based inactivation by tienilic acid.

  2003cited by this paper
• Real-time polymerase chain reaction analysis of CYP1B1 gene expression in human liver.

  2003cited by this paper
• Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes

  2003cited by this paper
• Strategies and Molecular Probes to Investigate the Role of Cytochrome P450 in Drug Metabolism

  2003cited by this paper
• Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles.

  2002cited by this paper
• Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism.

  2002influential reference
• Monoclonal antibodies specific and inhibitory to human cytochromes P450 2C8, 2C9, and 2C19.

  2001influential reference
• In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).

  2001cited by this paper
• Alternative splicing determines the function of CYP4F3 by switching substrate specificity.

  2001influential reference
• Histone Deacetylase Is a Direct Target of Valproic Acid, a Potent Anticonvulsant, Mood Stabilizer, and Teratogen*

  2001cited by this paper
• Metabolic profiling of valproic acid by cDNA-expressed human cytochrome P450 enzymes using negative-ion chemical ionization gas chromatography-mass spectrometry.

  2000cited by this paper
• An inhibitory monoclonal antibody to human cytochrome P450 2A6 defines its role in the metabolism of coumarin, 7-ethoxycoumarin and 4-nitroanisole in human liver.

  1999influential reference
• Chemistry and biotransformation

  1999cited by this paper
• Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action.

  1999influential reference
• Inhibitory monoclonal antibody to human cytochrome P450 2B6.

  1998influential reference
• Metabolism of arachidonic acid to 20-hydroxy-5,8,11, 14-eicosatetraenoic acid by P450 enzymes in human liver: involvement of CYP4F2 and CYP4A11.

  1998cited by this paper
• P450-catalyzed in-chain desaturation of valproic acid: isoform selectivity and mechanism of formation of Delta 3-valproic acid generated by baculovirus-expressed CYP3A1.

  1998influential reference
• Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines.

  1997cited by this paper
• Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation.

  1997cited by this paper
• Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid.

  1997influential reference
• A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes.

  1997influential reference
• Valproic acid hepatic fatalities. III. U.S. experience since 1986

  1996cited by this paper
• Cytotoxicity of unsaturated metabolites of valproic acid and protection by vitamins C and E in glutathione-depleted rat hepatocytes.

  1996cited by this paper
• Fluorinated analogues as mechanistic probes in valproic acid hepatotoxicity: hepatic microvesicular steatosis and glutathione status.

  1995cited by this paper
• CYP4 isozyme specificity and the relationship between omega-hydroxylation and terminal desaturation of valproic acid.

  1995influential reference
• Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes.

  1995influential reference
• Metabolism and pharmacokinetic studies of valproic acid using stable isotope techniques

  1993cited by this paper
• Effects of valproate and E-2-en-valproate on functional and morphological parameters of rat liver. II. Influence of phenobarbital comedication.

  1993cited by this paper
• Valproate (VPA) Metabolites in Various Clinical Conditions of Probable VPA‐Associated Hepatotoxicity

  1993cited by this paper
• Idiosyncratic Reactions to Valproate: Clinical Risk Patterns and Mechanisms of Toxicity

  1992cited by this paper
• Identification and characterization of the glutathione and N-acetylcysteine conjugates of (E)-2-propyl-2,4-pentadienoic acid, a toxic metabolite of valproic acid, in rats and humans.

  1991cited by this paper
• Metabolic activation of valproic acid and drug-mediated hepatotoxicity. Role of the terminal olefin, 2-n-propyl-4-pentenoic acid.

  1988cited by this paper
• Valproic acid hepatic fatalities

  1987cited by this paper
• Cytochrome P-450--catalyzed formation of delta 4-VPA, a toxic metabolite of valproic acid.

  1987cited by this paper
• Mechanism of zone-specific hepatic steatosis caused by valproate: inhibition of ketogenesis in periportal regions of the liver lobule.

  1986cited by this paper
• Metabolism of valproic acid by hepatic microsomal cytochrome P-450.

  1984cited by this paper
• The Hepatotoxicity of Valproic Acid and Its Metabolites in Rats. II. Intermediary and Valproic Acid Metabolism

  1984cited by this paper
• The Hepatotoxicity of Valproic Acid and Its Metabolites in Rats. I. Toxicologic, Biochemical and Histopathologic Studies

  1984cited by this paper
• The Toxicity of Metabolites of Sodium Valproate in Cultured Hepatocytes

  1983cited by this paper

• Real‐Time Monitoring of the Antiseizure Drug Valproic Acid Using a Novel Point‐Of‐Care Mass Spectrometry

  2025cites this paper
• Predictive biomarkers for valproic acid-induced hepatotoxicity in Chinese epileptics: the role of metabolites and genetic polymorphisms.

  2025cites this paper
• Prediction of key pathways in hepatocellular carcinoma (HCC): A machine learning approach using a sample pathway information matrix

  2025cites this paper
• Toxicological effects of cobalt on common carp: oxidative stress, ionic imbalance, fatty acid disruption, and gill histopathology

  2025cites this paper
• New insights into mechanisms of valproic acid-induced neurodevelopmental toxicity in autism spectrum disorder: An integrative network toxicology approach combined with in vivo validation.

  2025cites this paper
• Genetic and clinical factors associated with the metabolism of valproic acid in post-neurosurgery patients.

  2025cites this paper
• Review article: Hepatic steatosis and its associations with acute and chronic liver diseases

  2024cites this paper
• Pharmacogenetic Determinants of Valproic Acid Efficacy, Toxicity, and Serum Levels in Genetic Generalized Epilepsy

  2024cites this paper
• Factors Influencing Plasma Concentrations of Valproic Acid in Pediatric Patients With Epilepsy and the Clinical Significance of CYP2C9 Genotypes in Personalized Valproic Acid Therapy

  2024cites this paper
• Advances and Challenges in Modeling Cannabidiol Pharmacokinetics and Hepatotoxicity

  2024cites this paper
• Uncovering the toxicity mechanisms of a series of carboxylic acids in liver cells through computational and experimental approaches.

  2024cites this paper
• An Update on Stiripentol Mechanisms of Action: A Narrative Review

  2024cites this paper
• Formation of potentially toxic metabolites of drugs in reactions catalyzed by human drug-metabolizing enzymes

  2024cites this paper
• Mycorrhizal Symbiosis Can Change the Composition of Secondary Metabolites in Fruits of Solanum nigrum L.

  2024cites this paper
• Valproic Acid Inhibits Endoplasmic Reticulum Stress and Reduces Ferroptosis After Traumatic Brain Injury

  2024cites this paper
• The role of candidate pharmacogenetic variants in determining valproic acid efficacy, toxicity and concentrations in patients with epilepsy

  2024cites this paper
• Ethnic Aspects of Valproic Acid P-Oxidation

  2024cites this paper
• Evaluation of CYP2C19 Genetic Variant and Its Lack of Association with Valproic Acid Plasma Concentrations Among Zhuang and Han Schizophrenia Patients in Guangxi

  2024cites this paper
• Pharmacogenetic insights into ABCB1, ABCC2, CYP1A2, and CYP2B6 variants with epilepsy susceptibility among Egyptian Children: A retrospective case-control study.

  2024cites this paper
• An Retrospective Study of Commonly Prescribed Antiepileptic Drugs and it’s Interaction with Other Drugs which are Already in use Respect to Other Disease

  2024cites this paper
• Role of Pharmacogenetic Testing in the Risk and Safety Assessment of Valproates: The Ethnic Aspect (Review)

  2024cites this paper
• Pharmacokinetic characterisation of a valproate Autism Spectrum Disorder rat model in a context of co-exposure to α-Hexabromocyclododecane.

  2023cites this paper
• Therapeutic and Toxic Effects of Valproic Acid Metabolites

  2023cites this paper
• Effect of antibiotic-administration period on hepatic bile acid profile and expression of pharmacokinetic-related proteins in mouse liver, kidney, and brain capillaries.

  2023cites this paper
• Allelic and Genotype Frequencies of CYP2B6∗2 (64C > T) and CYP2B6∗3 (777C > A) in Three Dominant Ethnicities of the Iranian Population

  2023cites this paper
• Molecular Idiosyncratic Toxicology of Drugs in the Human Liver Compared with Animals: Basic Considerations

  2023cites this paper
• Simultaneous determination of 24 antiepileptic drugs and their active metabolites in human plasma by UHPLC-MS/MS.

  2023cites this paper
• Successful LC-MS/MS assay development and validation for determination of valproic acid and its metabolites supporting proactive pharmacovigilance.

  2023cites this paper
• Physiologically based mechanistic insight into differential risk of valproate hepatotoxicity between children and adults: A focus on ontogeny impact

  2023cites this paper
• Oxidative-stress and long-term hepatotoxicity: comparative study in Upcyte human hepatocytes and hepaRG cells

  2022cites this paper
• Drug Interactions Affecting Oral Anticoagulant Use

  2022cites this paper
• An individualized medication model of sodium valproate for patients with bipolar disorder based on machine learning and deep learning techniques

  2022cites this paper
• Targeting the epigenome in malignant melanoma: Facts, challenges and therapeutic promises.

  2022cites this paper
• In vitro evaluation suggests fenfluramine and norfenfluramine are unlikely to act as perpetrators of drug interactions

  2022cites this paper
• A comprehensive review on pharmacological applications and drug-induced toxicity of valproic acid

  2022cites this paper
• Effects of genetic polymorphism of drug-metabolizing enzymes on the plasma concentrations of antiepileptic drugs in Chinese population

  2022cites this paper
• Utilizing Large Electronic Medical Record Data Sets to Identify Novel Drug–Gene Interactions for Commonly Used Drugs

  2021cites this paper
• Title : Archaic introgression and variation in pharmacogenes and implications for local adaptation

  2021cites this paper
• Molecular Dynamics and MM-PBSA Studies for Deciphering Molecular Interactions of Valproic Acid with CYP2C9 Mutants F114L and I207T

  2021cites this paper
• Insights into Structural Modifications of Valproic Acid and Their Pharmacological Profile

  2021influential citation
• Effect of CYP2C19 polymorphisms on serum valproic level acid in Chinese Han patients with schizophrenia

  2021cites this paper
• Pharmacogenetic Variation in Neanderthals and Denisovans and Implications for Human Health and Response to Medications

  2021cites this paper
• Pharmacodynamic and pharmacokinetic interactions of hydroalcoholic leaf extract of Centella asiatica with valproate and phenytoin in experimental models of epilepsy in rats.

  2021cites this paper
• Human Family 1–4 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update

  2021cites this paper
• Considerations of HLA, Renal Failure, Valproic Acid Use, and Current Treatment Guidelines in Clozapine-Induced Agranulocytosis

  2021cites this paper
• Valproic Acid-Induced Liver Injury: A Case-Control Study from a Prospective Pharmacovigilance Program in a Tertiary Hospital

  2021cites this paper
• CYP2C9*3/*3 Gene Expression Affects the Total and Free Concentrations of Valproic Acid in Pediatric Patients with Epilepsy

  2021cites this paper
• Influence of UGT2B7 and UGT1A6 polymorphisms on plasma concentration to dose ratio of valproic acid in Chinese epileptic children

  2021cites this paper
• The association of adjusted plasma valproic acid concentration with CYP2C9 gene polymorphism in patients with epilepsy: a systematic review and meta-analysis

  2021cites this paper
• A narrative review of the importance of pharmacokinetics and drug–drug interactions of preventive therapies in migraine management

  2021cites this paper
• Mechanism of idiosyncratic drug induced liver injury (DILI): unresolved basic issues

  2020cites this paper
• Effect of Genetic Polymorphisms of CYP2C19 on the Steady-state Serum Concentrations of Valproic Acid in Chinese Han Patients With Schizophrenia

  2020cites this paper
• Estudio de genes candidatos sobre la efectividad y seguridad de la medicación anticonvulsiva en un grupo de pacientes colombianos afectados de epilepsia

  2020influential citation
• Valproic acid as an anticancer therapy-sensitizing agent

  2020cites this paper
• Testing association of rare genetic variants with resistance to three common antiseizure medications

  2020cites this paper
• Impact of Age and Genotype on Serum Concentrations of Valproic Acid and Its Hepatotoxic Metabolites in Chinese Pediatric Patients with Epilepsy.

  2020cites this paper
• Using high-resolution Twin-Ion Metabolite Extraction (HiTIME) mass spectrometry with stable isotope labelling to investigate the metabolism of valproic acid in vivo

  2019cites this paper
• Estimation of apparent clearance of valproic acid in adult Saudi patients

  2019cites this paper
• Valproic Acid and the Liver Injury in Patients with Epilepsy: An Update.

  2019cites this paper
• Rhabdomyolysis and Hepatotoxicity From Valproic Acid: Case Reports

  2019cites this paper
• El ácido valproico como agente sensibilizador al tratamiento anticáncer.

  2019cites this paper
• Identification of prognostic biomarkers for patients withhepatocellular carcinoma after hepatectomy

  2019cites this paper
• Integrated 'omics analysis reveals new drug-induced mitochondrial perturbations in human hepatocytes.

  2018cites this paper
• P450 Pharmacogenetics in Indigenous North American Populations

  2018cites this paper
• Risk Factors for Valproic Acid‐induced Hyperammonaemia in Chinese Paediatric Patients with Epilepsy

  2018cites this paper
• The prognostic value of CYP2C subfamily genes in hepatocellular carcinoma

  2018cites this paper
• Effects of valproate on reproductive endocrine function in male patients with epilepsy: A systematic review and meta-analysis.

  2018cites this paper
• Long-term and mechanistic evaluation of drug-induced liver injury in Upcyte human hepatocytes

  2018cites this paper
• High-dose quetiapine and therapeutic monitoring

  2018cites this paper
• Effect of CYP2C19, UGT1A8, and UGT2B7 on valproic acid clearance in children with epilepsy: a population pharmacokinetic model

  2018cites this paper
• Clinical Pharmacokinetics and Drug–Drug Interactions of Elbasvir/Grazoprevir

  2018cites this paper
• Relevance of CYP2C9 Function in Valproate Therapy

  2018cites this paper
• Subtherapeutic valproic acid plasma concentrations under concomitant dipyrone therapy in an epilepsy patient—a case report

  2018cites this paper
• Comparison of LC‐MS/MS vs chemiluminescent microparticle immunoassay in measuring the valproic acid concentration in plasma of epilepsy patients in a new perspective

  2018cites this paper
• Predictors of Variation in CYP2A6 mRNA, Protein, and Enzyme Activity in a Human Liver Bank: Influence of Genetic and Nongenetic Factors

  2017cites this paper
• Genetic polymorphisms and valproic acid plasma concentration in children with epilepsy on valproic acid monotherapy.

  2017cites this paper
• The pharmacogenomics of valproic acid

  2017cites this paper
• BIOLOGICAL MARKERS OF THE ANTIEPILEPTIC DRUGS EFFICACY AND SAFETY: PHARMACOGENETICS AND PHARMACOKINETICS

  2017influential citation
• Effect of UGT2B7 genotypes on plasma concentration of valproic acid: a meta-analysis

  2017cites this paper
• Pharmacogenomics in epilepsy

  2017cites this paper
• Association of CYP2C9, CYP2A6, ACSM2A, and CPT1A gene polymorphisms with adverse effects of valproic acid in Chinese patients with epilepsy.

  2017cites this paper
• Early post-traumatic seizures are associated with valproic acid plasma concentrations and UGT1A6/CYP2C9 genetic polymorphisms in patients with severe traumatic brain injury

  2017cites this paper
• CYP3A5*3 Polymorphism May Influence the Concentration of Valproic Acid

  2017cites this paper
• Oxidative Drug Metabolism by Mammalian Cytochrome P450 Enzymes Using Their Monooxygenase and Peroxygenase Functions

  2017cites this paper
• Variation in CYP2A6 Activity and Personalized Medicine

  2017cites this paper
• Valproic Acid Metabolism and its Consequences on Sexual Functions.

  2016cites this paper
• Title : Predictors of variation in CYP 2 A 6 mRNA , protein , and enzyme activity in a human liver bank : influence of genetic and non-genetic factors

  2016cites this paper
• Impact of age, gender and CYP2C9/2C19 genotypes on dose-adjusted steady-state serum concentrations of valproic acid—a large-scale study based on naturalistic therapeutic drug monitoring data

  2016cites this paper
• A Sensitive Triple Quadrupole Liquid Chromatography Mass Spectrometric Method for the Estimation of Valproic Acid in K2EDTA Human Plasma using Furosemide as the Internal Standard

  2016cites this paper
• Pharmacogenomics and histone deacetylase inhibitors.

  2016cites this paper
• Insights into CYP2B6-mediated drug–drug interactions

  2016cites this paper
• Amino Acid Promoieties Alter Valproic Acid Pharmacokinetics and Enable Extended Brain Exposure

  2016cites this paper
• Effects of UGT1A6 and GABRA1 on Standardized Valproic Acid Plasma Concentrations and Treatment Effect in Children With Epilepsy in China

  2016cites this paper
• TERATOGENESIS OF ANTIEPILEPTIC DRUGS: REVIEW AND CLINICAL CASES

  2016cites this paper
• The influence of CYP2C9, CYP2C19 and ABCB1 polymorphisms on the plasma concentrations of valproic acid in epileptic patients.

  2016cites this paper
• Molekulare Untersuchungen zur Spezies-spezifischen Toxizität entwicklungsneurotoxischer Substanzen

  2015cites this paper
• Clinical significance of CYP2C9‐status guided valproic acid therapy in children

  2015cites this paper
• [A Woman Experienced Severe Thrombocytopenia When Treated With Fluvastatin].

  2015cites this paper
• Phenoconversion of CYP 2 C 9 in epilepsy limits the predictive value of 2 CYP 2 C 9 genotype in optimizing valproate therapy 3 4

  2015cites this paper
• A simple validated RP-HPLC bioanalytical method for the quantitative determination of a novel valproic acid arylamide derivative in rat hepatic microsomes.

  2015cites this paper